StreetInsider.com News Articles

Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 15 Oct 2026 16:05:00 -0400

GRAND RAPIDS, Mich., Oct. 15, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the third quarter of 2026 after market close on Thursday, November 5, 2026.

Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 15 Oct 2026 16:05:00 -0400

Form 8-K SHOULDER INNOVATIONS, For: Oct 08

Thu, 08 Oct 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20261008/27163506.html

Form 8-K SHOULDER INNOVATIONS, For: Oct 08

Thu, 08 Oct 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20261008/27163506.html

Shoulder Innovations begins limited release of InSet Go glenoid implant

Thu, 08 Oct 2026 07:00:53 -0400

Shoulder Innovations, Inc. (NYSE: SI) announced the initiation of a limited user release of its InSet® Go glenoid implant, a next-generation device for use in anatomic shoulder arthroplasty procedures.

The first surgical case using the InSet® Go was performed by Robert Gillespie, MD, at University Hospitals Cleveland Medical Center in Cleveland, Ohio.

According to the company, the InSet® Go is based on a glenoid technology originally invented more than 20 years ago by Stephen Gunther, MD. The design places the implant within a circumferential rim of bone, which the company says addresses glenoid implant loosening, described as the leading cause of failure

Shoulder Innovations Initiates Commercial Launch of the InSet® Go

Thu, 08 Oct 2026 07:00:00 -0400

Limited User Release of the Company's Next-Generation InSet® Glenoid Implant Follows Successful Completion of First Surgical Case

GRAND RAPIDS, Mich., Oct. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has initiated a

Shoulder Innovations Initiates Commercial Launch of the InSet® Go

Thu, 08 Oct 2026 07:00:00 -0400

Limited User Release of the Company's Next-Generation InSet® Glenoid Implant Follows Successful Completion of First Surgical Case

Form 4 SHOULDER INNOVATIONS, For: Oct 05 Filed by: Tansey Casey M

Tue, 06 Oct 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20261006/27156292.html

Form 4 SHOULDER INNOVATIONS, For: Oct 05 Filed by: Sidow Kevin K.

Tue, 06 Oct 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20261006/27156134.html

Form 4 SHOULDER INNOVATIONS, For: Oct 05 Filed by: Hykes Andrew

Tue, 06 Oct 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20261006/27156108.html

Form 4 SHOULDER INNOVATIONS, For: Oct 05 Filed by: BUCKMAN PAUL

Tue, 06 Oct 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20261006/27156078.html

Form 4 SHOULDER INNOVATIONS, For: Sep 14 Filed by: Ball Robert Joseph

Mon, 14 Sep 2026 20:23:00 -0400

si-local-file:///var/storage/secattach/20260914/27059764.html

Form 144 SHOULDER INNOVATIONS, Filed by: Ball Robert Joseph

Mon, 14 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260914/27058672.html

Form 144 SHOULDER INNOVATIONS, Filed by: Ball Robert Joseph

Mon, 14 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260914/27058672.html

Shoulder Innovations wins FDA clearance for titanium shoulder implant

Thu, 10 Sep 2026 16:05:36 -0400

Shoulder Innovations, Inc. (NYSE: SI) received U.S. Food and Drug Administration 510(k) clearance for its N-22 Humeral Head, a titanium implant designed for patients with metal hypersensitivity, and simultaneously launched the product commercially, according to a press release dated Sept. 10, 2026.

The N-22 Humeral Head is intended for use in anatomic total shoulder arthroplasty procedures. The company states that approximately 10% to 15% of the general population tests positive for metal hypersensitivity, which can result in persistent pain or other allergic symptoms associated with metal implants.

The clearance follows the company's N-22 Glenosphere implant, which received FDA clearance in January 2026

Shoulder Innovations wins FDA clearance for titanium shoulder implant

Thu, 10 Sep 2026 16:05:36 -0400

The clearance follows the company's N-22 Glenosphere implant, which received FDA clearance in January 2026

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Thu, 10 Sep 2026 16:05:00 -0400

Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients

GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity. Alongside the clearance, the company also announced the product's full commercial launch.

Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Thu, 10 Sep 2026 16:05:00 -0400

Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients

Shoulder Innovations strikes exclusive deal with ALM Ortho for custom implants

Wed, 09 Sep 2026 16:25:09 -0400

Shoulder Innovations, Inc. (NYSE: SI) announced an exclusive collaboration with ALM Ortho, Inc. to develop patient-specific titanium shoulder implants for complex revision cases and severe shoulder deformity, according to a press release dated Sept. 9, 2026.

Under the agreement, Shoulder Innovations holds exclusive rights for upper extremity applications of ALM Ortho's solutions in the United States. ALM Ortho will design, manufacture, and deliver implants on a case-by-case basis using patient imaging data, while Shoulder Innovations will use its surgeon relationships and sales organization to identify cases and connect surgeons and facilities with the product.

Rob Ball, CEO of Shoulder Innovations, said the

Shoulder Innovations strikes exclusive deal with ALM Ortho for custom implants

Wed, 09 Sep 2026 16:25:09 -0400

Rob Ball, CEO of Shoulder Innovations, said the

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

Wed, 09 Sep 2026 16:24:00 -0400

GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has entered into an exclusive collaboration with ALM Ortho, Inc. ("ALM Ortho"), a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for the treatment of severe shoulder deformity and other highly complex revision cases, circumstances for which no adequate solution currently exists.

Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures

Wed, 09 Sep 2026 16:24:00 -0400

Shoulder Innovations settles patent dispute with Catalyst OrthoScience

Tue, 08 Sep 2026 16:06:51 -0400

Shoulder Innovations, Inc. (NYSE: SI) announced it has reached a settlement agreement with Catalyst OrthoScience Inc. to resolve all outstanding patent litigation between the two companies, according to a press release dated Sept. 8, 2026.

The financial terms of the settlement were not disclosed.

"We are pleased to have reached a resolution with Catalyst that provides an agreeable solution to this patent dispute," said Rob Ball, CEO of Shoulder Innovations. "Protecting our intellectual property is fundamental to ensuring that the investments we make in innovation continue to benefit Shoulder Innovations stakeholders, particularly including surgeons and patients."

Shoulder Innovations describes itself as a commercial-stage

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

Tue, 08 Sep 2026 16:05:00 -0400

GRAND RAPIDS, Mich., Sept. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that it has entered into a settlement agreement with Catalyst OrthoScience Inc. ("Catalyst") to resolve all outstanding patent litigation between the two companies. The terms of the settlement agreement are confidential.

Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience

Tue, 08 Sep 2026 16:05:00 -0400